SYDNEY, Australia, Nov. 28, 2017 (GLOBE NEWSWIRE) -- We refer to shareholder approval granted at the Companyβs Annual General Meeting held on 17 November 2017 to change the name of the...
SYDNEY, Australia, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (βPrimaβ, the βCompanyβ) announces the grant of patent number 2604275 entitled βUse of...
SYDNEY, Australia, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (βPrimaβ or the βCompanyβ) has announced a rebranding of the Company from Prima BioMed Ltd to...
SYDNEY, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (βPrimaβ) is pleased to announce that it held a Pre-Investigational New Drug Application...
SYDNEY, Australia, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (βPrimaβ) is pleased to announce the presentation of new data from its TACTI-mel Phase I...
SYDNEY, Australia, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (βPrimaβ) announces that Dr. FrΓ©dΓ©ric Triebel, Primaβs Chief Scientific Officer and Medical...
SYDNEY, Australia, Oct. 19, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ: PBMD) (βPrimaβ) announces that Dr. FrΓ©dΓ©ric Triebel, Primaβs Chief Scientific Officer & Medical...
SYDNEY, Australia, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (βPrimaβ) announces that new data investigating the use of eftilagimod alpha (IMP321), the...
SYDNEY, Australia, Sept. 08, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (βPrimaβ, the βCompanyβ) announces the grant of Japanese patent no. 6177735 entitled βCytotoxic...
SYDNEY, Australia, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (βPrimaβ, the βCompanyβ) announces the grant of patent number 6169734 entitled βUse of...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.